Clinical trial • Phase III • Oncology
Rilvegostomig for Advanced solid tumors
Phase III trial of Rilvegostomig for Advanced solid tumors. 27 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Advanced solid tumors
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 12-09-2025
- First CTIS Authorization Date
- 15-01-2026
Trial design
Phase III trial across 4 sites in Spain.
- Target Sample Size
- 27
Eligibility
Recruits 27 Vulnerable populations selected (isVulnerablePopulationSelected=true); no details on consent or assent handling provided in the source..
- Vulnerable Population
- Vulnerable populations selected (isVulnerablePopulationSelected=true); no details on consent or assent handling provided in the source.
Recruitment
- Planned Sample Size
- 27
- Recruitment Window Months
- 53
Geography
- Total Number Of Sites
- 4
- Total Number Of Participants
- 13
Spain
- Earliest CTIS Part Ii Submission Date
- 01-12-2025
- Latest Decision Or Authorization Date
- 30-03-2026
- Processing Time Days
- 119
- Number Of Sites
- 4
- Number Of Participants
- 13
Sites
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- 7003: Medical Oncology
- Principal Investigator Name
- Elena Garralda Cabanas
- Principal Investigator Email
- egarralda@vhio.net
- Contact Person Name
- Elena Garralda Cabanas
- Contact Person Email
- egarralda@vhio.net
- Site Name
- Hospital Clinic De Barcelona
- Department Name
- 7004: Oncología Médica
- Principal Investigator Name
- Ivan Victoria Ruiz
- Principal Investigator Email
- ivictori@recerca.clinic.cat
- Contact Person Name
- Ivan Victoria Ruiz
- Contact Person Email
- ivictori@recerca.clinic.cat
- Site Name
- Clinica Universidad De Navarra
- Department Name
- 7001: Oncología
- Principal Investigator Name
- Eduardo Castañon Alvarez
- Principal Investigator Email
- ecastanon@unav.es
- Contact Person Name
- Eduardo Castañon Alvarez
- Contact Person Email
- ecastanon@unav.es
- Site Name
- Hospital Universitario Fundacion Jimenez Diaz
- Department Name
- 7002: Oncología
- Principal Investigator Name
- Victor Moreno Garcia
- Principal Investigator Email
- victor.moreno@startmadrid.com
- Contact Person Name
- Victor Moreno Garcia
- Contact Person Email
- victor.moreno@startmadrid.com
Sponsor
Primary sponsor
- Full Name
- AstraZeneca AB
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Sweden
Investigational products
- Investigational Product Name
- Rilvegostomig
- Routes Of Administration
- Subcutaneous
- Route
- Subcutaneous
Related trials
Other published trials that may interest you.